US 11,946,056 B2
Optimized vector for delivery in microbial populations
Antoine Decrulle, Paris (FR); Jesus Fernandez Rodriguez, Paris (FR); Xavier Duportet, Paris (FR); and David Bikard, Paris (FR)
Assigned to ELIGO BIOSCIENCE, Paris (FR); and INSTITUT PASTEUR, Paris (FR)
Filed by Eligo Bioscience, Paris (FR); and Institut Pasteur, Paris (FR)
Filed on Jun. 23, 2021, as Appl. No. 17/356,079.
Application 17/356,079 is a continuation of application No. 17/017,111, filed on Sep. 10, 2020, granted, now 11,078,490.
Application 17/017,111 is a continuation of application No. 16/527,762, filed on Jul. 31, 2019, granted, now 10,808,254, issued on Oct. 20, 2020.
Application 16/527,762 is a continuation of application No. PCT/EP2018/052662, filed on Feb. 2, 2018.
Claims priority of application No. 17305126 (EP), filed on Feb. 3, 2017.
Prior Publication US 2021/0380993 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/73 (2006.01); A61K 35/76 (2015.01); A61P 31/04 (2006.01); C12N 7/00 (2006.01); C12N 15/74 (2006.01)
CPC C12N 15/73 (2013.01) [A61K 35/76 (2013.01); A61P 31/04 (2018.01); C12N 7/00 (2013.01); C12N 15/74 (2013.01); C12N 2795/10332 (2013.01); C12N 2800/10 (2013.01); C12N 2800/101 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method for delivering an engineered vector into a group of bacteria of interest in a subject, wherein the method comprises administering to the subject an engineered vector, thereby delivering said engineered vector to a bacterium of said group of bacteria of interest, wherein said engineered vector is an engineered bacteriophage, packaged phagemid, bacteriophage genome or phagemid, which has been genetically engineered to remove, in non-coding regions and optionally in coding regions, at least one restriction site of at least one restriction enzyme which is frequently encoded in said group of bacteria of interest, wherein said at least one restriction site is removed by changing the sequence so as to prevent the recognition by the corresponding restriction enzyme and wherein the efficiency of DNA delivery into the group of bacteria by the engineered vector is increased as compared to DNA delivery into the group of bacteria by the engineered vector prior to removal of the at least one restriction site.